EUVIMEDEUVIMED entdecken
Crossref

GPR146 as a therapeutic target: Linking lipid metabolism with macrophage inflammation in atherosclerosis

Qing Liu, Yifei Wang, Yu Geng, Yajun Xue, Changhua Lv, Jiacheng Ren, Zijuan Zhao, Tingting Lv, Ping Zhang

Biochemical Pharmacology · 2026-12 · 254 · 118600

DOI: 10.1016/j.bcp.2026.118600 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-12. Verfasst von Qing Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medical College, Qinghai University, Xining, China; Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medici…. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Beijing Natural Science Foundation, Clinical Medicine Development of Special Funding Support of Beijing Municipal Hospital Management Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerosis is driven by dyslipidemia and chronic inflammation. GPR146 has emerged as a regulator of cholesterol metabolism; however, whether GPR146 links lipid metabolism with macrophage inflammation during atherosclerosis remains unclear. Apolipoprotein E-deficient (ApoE-/-) mice were fed a high-fat diet for 12 weeks, followed by 4 weeks of intervention with adeno-associated virus (AAV)-mediated hepatic GPR146 knockdown or rosuvastatin treatment. Atherosclerotic lesions and plaque composition were assessed using Oil Red O staining and immunofluorescence. Lipid profiles, oxidized low-density lipoprotein (ox-LDL), and inflammatory markers were evaluated using enzymatic assays, ELISA, and qPCR, respectively. In ox-LDL-stimulated THP-1-derived macrophages, GPR146 was silenced to examine lipid accumulation, inflammatory responses, transcriptomic alterations, and the potential involvement of the JAK-STAT signaling pathway. GPR146 expression increased in atherosclerotic lesions, particularly in macrophage-rich regions. Hepatic GPR146 knockdown reduced atherosclerotic lesion burden, circulating total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels, ox-LDL accumulation, and inflammatory activation within plaques. In macrophages, GPR146 silencing suppressed ox-LDL-induced lipid accumulation, accompanied by reduced CD36 expression and decreased foam cell formation. GPR146 silencing also attenuated pro-inflammatory macrophage activation, as evidenced by reduced expression of inflammatory mediators. Transcriptomic analysis implicated JAK-STAT signaling, with reduced JAK2 and STAT3 expression following GPR146 silencing. Pharmacological inhibition of the JAK-STAT signaling partially recapitulated the anti-inflammatory effects associated with GPR146 knockdown. Together, these findings suggest that GPR146 contributes to lipid metabolic regulation and macrophage inflammatory responses during atherosclerosis and may represent a therapeutic target warranting further investigation.

Schlagwörter

Stichwörter der Autor:innen

AtherosclerosisGPR146ImmunometabolismLipid metabolismMacrophage inflammation

Autor:innen und Institutionen

  • Clinical Medical College, Qinghai University, Xining, China; Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China; Department of General Practic…
  • Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
  • Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China. Electronic address: lvtingting0616@163.com.
  • Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China. Electronic address: zhpdoc@126.com.

Förderung

  • Beijing Natural Science Foundation
  • Clinical Medicine Development of Special Funding Support of Beijing Municipal Hospital Management Center

Zitieren

APA

Liu, Q., Wang, Y., Geng, Y., Xue, Y., Lv, C., Ren, J., Zhao, Z., Lv, T., & Zhang, P. (2026). GPR146 as a therapeutic target: Linking lipid metabolism with macrophage inflammation in atherosclerosis. Biochemical Pharmacology, 254, 118600. https://doi.org/10.1016/j.bcp.2026.118600

Vancouver

Liu Q, Wang Y, Geng Y, Xue Y, Lv C, Ren J, et al. GPR146 as a therapeutic target: Linking lipid metabolism with macrophage inflammation in atherosclerosis. Biochemical Pharmacology. 2026;254:118600. doi:10.1016/j.bcp.2026.118600

BibTeX
@article{Liu2026,
  author = {Liu, Qing and Wang, Yifei and Geng, Yu and Xue, Yajun and Lv, Changhua and Ren, Jiacheng and Zhao, Zijuan and Lv, Tingting and Zhang, Ping},
  title = {GPR146 as a therapeutic target: Linking lipid metabolism with macrophage inflammation in atherosclerosis},
  journal = {Biochemical Pharmacology},
  year = {2026},
  volume = {254},
  pages = {118600},
  doi = {10.1016/j.bcp.2026.118600}
}
Kostenlos starten →